drugset / Trial / NCT02251197

Safety and Tolerability of BIII 890 in Patients With Acute Ischemic Stroke

NCT02251197

Phase 2 Completed 97 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

The objective of this study is to assess the safety, tolerability and pharmacokinetic characteristics of BIII 890 after intravenous infusion in acute ischemic stroke patients.

Timeline

Start
2001-07
Primary completion
2002-10
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Crobenetine Small molecule Intravenous

Indications